Entrepreneurship and innovation enable Weill Cornell Medicine to bring discoveries to patients faster.

Weill Cornell Medicine investigators enjoy a robust pipeline of dedicated programs capable of taking early discoveries made in academic labs to U.S. Food and Drug Administration-approved testing in clinical trials. Other new initiatives are designed to foster a culture of entrepreneurship and to build the next generation of leaders in life sciences industries and new ventures. 


The Entrepreneurs

Fostering a culture of innovation, Weill Cornell Medicine is making it faster and easier for researchers to move their discoveries from bench to bedside.

Symposium Highlights Weill Cornell Medicine’s Efforts to Foster Drug Discovery

The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators.

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

The Tri-Institutional Therapeutics Discovery Institute, a venture between New York City institutions, creates an accelerated path to treat disease.

Daedalus Fund Supports Eight Investigators

Eight Weill Cornell Medicine faculty members have been selected for the fifth round of the Daedalus Fund for Innovation awards.
Views on Innovation
Dr. Augustine M.K. Choi, the Stephen and Suzanne Weiss Dean
We have recently implemented many initiatives to help our faculty translate their research findings into innovative treatments and therapies for our patients.
Dr. Katherine Hajjar, Associate Dean for Faculty Development
Support from the Daedalus Fund for Innovation is essential, because the usual funding agencies do not support this kind of high-risk applied research.
Dr. William Povino, CEO of Bridge Medicines
Tri-Institutional Therapeutics Discovery Institute and Bridge Medicines put the skill of a pharmaceutical company on the campuses of three great institutions.
Larry Schlossman, Managing Director of BioPharma Alliances and Research Collaborations
We have a fully integrated entrepreneurship ecosystem here. And we really work as a team to help faculty decide what is the best path forward for their project.